The burden of chronic kidney disease (CKD) and its risk factors are projected to rise in
parallel with the rapidly ageing global population. By 2050, the prevalence of CKD category …

Diabetic kidney disease (DKD) is a chronic microvascular complication in patients with
diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD) …

Chronic kidney disease is a global public health problem, involving about 10% of the global
population. 1 The awareness of this major burden is relatively recent and still incomplete …

Abstract Aim This Phase I study evaluated the safety and early efficacy of an aldosterone
synthase inhibitor (BI 690517) in people with diabetes and albuminuric chronic kidney …

The target-hypertension (Target-HTN) trial investigated the efficacy and safety of
lorundrostat, an aldosterone synthase inhibitor, as an antihypertensive. Cohort 1 of the trial …

Aldosterone synthase inhibition with or without background sodium-glucose cotransporter-2
inhibition in CKD: a Phase II clinica Page 1 Aldosterone synthase inhibition with or without …

Chronic kidney disease (CKD) currently affects approximately 850 million people globally
and is continuing to increase in prevalence as well as in importance as a cause of death …

Abstract Aldosterone synthase (CYP11B2) is the rate-limiting enzyme in aldosterone
production. In recent years, CYP11B2 has become an appealing target for treating …

Background Primary aldosteronism (PA) is caused by autonomous aldosterone
overproduction and characterised by uncontrolled hypertension. There are currently no …

Renin–angiotensin–aldosterone system (RAAS) inhibitors are standard care in patients with
hypertension, heart failure or chronic kidney disease (CKD). Although we have studied the …